in young children.
Significant morbidity can occur among children during outbreaks of influenza B virus infection (14, 24) . Community epidemics of influenza B have resulted in high rates of school absenteeism (10) . Infants also may develop severe infection, leading to extensive evaluation to rule out bacterial sepsis (9, 10, 24) . Influenza B virus infections in young children may be complicated by gastrointestinal complaints, otitis media, high fever, acute myositis, and Reye syndrome (2, 7, 10, 12, 15, 17, 23, 24) . Severe illness and death have occurred among persons of all ages infected with influenza B virus (2, 19, 22) .
Inactivated influenza B virus vaccines have not provided the same level of immunity as have inactivated or live attenuated influenza A virus vaccines (4, 15) . Recombinant strains of cold-adapted (ca) live influenza A and B virus vaccine candidates for intranasal administration have been developed as a possible alternative to parenteral inactivated vaccine. Several studies with live attenuated reassortant ca influenza A virus vaccine and one study with ca influenza B virus vaccine have shown them to be safe and antigenic in infants and young children (1, 3, 8, 20, 21, 25) . The significant morbidity associated with outbreaks of influenza B virus infection confirms the need for a safe, antigenic live attenuated ca influenza B virus vaccine (18, 25 included in the daily home surveillance to assess the presence of other viruses in the community. Because of concern about a relationship between influenza B virus infection and Reye syndrome, serum transaminase levels (aspartate aminotransferase and alanine aminotransferase) in 39 vaccinees were determined during the initial screening process and on day 14 of the study. Virus isolation and serologic tests. Nasopharyngeal swab samples were inoculated onto primary rhesus monkey kidney (RMK) cells in duplicate and incubated at 32°C for 14 days. RMK cell layers were hemadsorbed with 0.4% guinea pig erythrocytes on days 5, 9, and 14 after inoculation for isolation of influenza B/Texas/84 ca reassortant virus. Each of the positive specimens was identified by a hemagglutinin inhibition (HAI) test and quantitated by TCID50 in RMK cells (1, 3) .
Serum samples were collected from each vaccinee before and 28 days after vaccination to evaluate their HAI and enzyme-linked immunosorbent assay (ELISA) antibody responses to influenza B virus infection by previously described methods (1, 3) . HAI tests were done with homologous influenza B/Texas/ca reassortant virus which had been passaged once in MDCK tissue culture cells. Purified hemagglutinin from influenza B/Yamagata virus (a gift from Connaught Laboratories, Inc., Swiftwater, Pa.) was used to coat the microtiter plates for the ELISA. Children who had HAI titers of <1:4 were considered seronegative.
Genetic stability of vaccine virus. Vaccine virus recovered from children who shed virus for prolonged periods was tested for the temperature-sensitive (ts) phenotype by previously described methods (5, 16 Sera for measurement of aspartate aminotransferase and alanine aminotransferase were obtained from 28 seropositive children and 16 seronegative children before vaccination and 14 days after vaccination. No elevations in aspartate aminotransferase or alanine aminotransferase levels occurred among the 13 seropositive children who were infected with vaccine virus or among the 10 seronegative children who were infected by vaccine virus.
Phenotypic stability of vaccine virus. In order to evaluate the phenotypic stability of vaccine virus shed for prolonged intervals by young children, isolates obtained from 10 vaccinees 2 to 8 days postvaccination were tested for genotype and phenotype ( (13) .
One other ca influenza B virus derived from the parent ca influenza B/Ann Arbor/1/66 virus has been evaluated in adults: influenza B/Ann Arbor/1/86 ca reassortant virus (CRB-117) has the hemagglutinin and neuraminidase genes from the influenza B/Ann Arbor/1/86 virus. In studies of adults vaccinated with influenza B/Ann Arbor/1/86 ca reassortant virus, the HID50 ranged from 106.2 to 106.5 TCID50 (4, 8) . Influenza B/Ann Arbor/1/86 ca reassortant virus was safe in children, but the infectivity of this virus was greater than the infectivity we observed for influenza B/Texas/84 ca reassortant virus. In contrast to a HID50 of 104-5 TCID50 for seronegative children in the present study, the HID50 for influenza B/Ann Arbor/1/86 ca reassortant virus was 102.5 TCID50 (8) . The reason for the higher infectivity of the influenza B/Ann Arbor/1/86 ca reassortant virus among children in comparison with the influenza B/Texas/84 ca reassortant virus is not known, since influenza B/Ann Arbor/ 1/86 ca reassortant and influenza B/Texas/84 ca reassortant viruses are derived from the same parent ca strain and differ only in the hemagglutinin and neuraminidase genes. Apparently, the hemagglutinin or neuraminidase influences the infectivity in seronegative children.
The safety of influenza B/Texas/84 ca reassortant virus was demonstrated in this study. The occurrence of respiratory symptoms was no more frequent among either seropositive or seronegative vaccinees than among unvaccinated controls. Similar safety data on other cold-adapted reassortant influenza A or B virus vaccines have been reported elsewhere (1, 3, 4, 8, 13) . In the present study, the quantity and duration of shedding of vaccine virus were markedly less than those reported for wild-type influenza B virus (4, 11 
